Shravan Dave
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shravan Dave has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Rohit Loomba
MASLD Research Center, Division of Gastroenterology and Hepatology, University of California, San Diego, La Jolla, CA, 92037
3 shared publications Abbey Barnard
NAFLD Research Center Division of Gastroenterology and Hepatology Department of Medicine University of California at San Diego San Diego California USA
2 shared publications- Veeral Ajmera
MASLD Research Center, Division of Gastroenterology and Hepatology University of California at San Diego La Jolla California USA
2 shared publications Abdul M. Majzoub
Division of Internal Medicine Conemaugh Memorial Medical Center Johnstown Pennsylvania USA
1 shared publication- Aijaz Ahmed
Division of Gastroenterology and Hepatology Stanford University School of Medicine Stanford California USA
1 shared publication - Amanda Baumgartner
Nonalcoholic Fatty Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA
1 shared publication
Latest Publications
- 14 February 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (7) , 1140-1151
Clinical Trial to Assess the Safety and Tolerability of Anti‐IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol‐Associated Liver Disease
Background: There are no FDA‐approved therapies for alcohol‐associated liver disease (ALD). Preclinical studies indicate that blocking IL‐23/IL‐17 signalling may reverse liver injury. Guselkumab, an IL‐23‐specific antibody approved for psoriasis, may be beneficial for ALD.Aims: We aimed to assess the safety and tolerability of guselkumab in patients with ALD.Methods: This phase‐1 dose‐escalation study included patients with ≥ 2 DSM‐5 criteria for alcohol use disorder, significant steatosis (MRI‐PDFF ≥ 8%) and MRE < 3.63 kPa (to exclude advanced disease). Guselkumab was given subcutaneously on Days 1 and 29 in 30, 70 or 100 mg dose cohorts. Primary endpoints were adverse events (AEs) and dose‐limiting toxicity.Results: We enrolled 13 patients (three 30 mg, three 70 mg, and seven 100 mg). Eleven completed the study and two early discontinued in the 100 mg group. Of them, 77% were men, and the median age was 53 [IQR 49–61] years. The median MRI‐PDFF and MRE were 18.4% [IQR 8.4%–34.0%] and 2.5 [2.2–2.6] kPa, respectively. The most frequent AEs were hyperuricemia (13%, mild only) and elevated lipase (11%, mild and moderate). There were no serious adverse events or significant variations in liver enzymes. There was a suppression of peripheral interleukin (IL)‐17, IL‐23, IL‐1b and TNF‐α in the 70 and 100 mg groups, and a significant decrease in alcohol consumption over time (AUDIT‐C: 6 [3–7] vs. 5 [1–6], p = 0.023).Conclusions: Guselkumab is safe in doses up to 100 mg and may reduce inflammation markers in ALD. These findings support further phase 2 studies to evaluate the efficacy of guselkumab in ALD, particularly in patients with severe phenotypes.
- 14 February 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (7) , 1140-1151
Clinical Trial to Assess the Safety and Tolerability of Anti‐IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol‐Associated Liver Disease
Background: There are no FDA‐approved therapies for alcohol‐associated liver disease (ALD). Preclinical studies indicate that blocking IL‐23/IL‐17 signalling may reverse liver injury. Guselkumab, an IL‐23‐specific antibody approved for psoriasis, may be beneficial for ALD.Aims: We aimed to assess the safety and tolerability of guselkumab in patients with ALD.Methods: This phase‐1 dose‐escalation study included patients with ≥ 2 DSM‐5 criteria for alcohol use disorder, significant steatosis (MRI‐PDFF ≥ 8%) and MRE < 3.63 kPa (to exclude advanced disease). Guselkumab was given subcutaneously on Days 1 and 29 in 30, 70 or 100 mg dose cohorts. Primary endpoints were adverse events (AEs) and dose‐limiting toxicity.Results: We enrolled 13 patients (three 30 mg, three 70 mg, and seven 100 mg). Eleven completed the study and two early discontinued in the 100 mg group. Of them, 77% were men, and the median age was 53 [IQR 49–61] years. The median MRI‐PDFF and MRE were 18.4% [IQR 8.4%–34.0%] and 2.5 [2.2–2.6] kPa, respectively. The most frequent AEs were hyperuricemia (13%, mild only) and elevated lipase (11%, mild and moderate). There were no serious adverse events or significant variations in liver enzymes. There was a suppression of peripheral interleukin (IL)‐17, IL‐23, IL‐1b and TNF‐α in the 70 and 100 mg groups, and a significant decrease in alcohol consumption over time (AUDIT‐C: 6 [3–7] vs. 5 [1–6], p = 0.023).Conclusions: Guselkumab is safe in doses up to 100 mg and may reduce inflammation markers in ALD. These findings support further phase 2 studies to evaluate the efficacy of guselkumab in ALD, particularly in patients with severe phenotypes.
- 14 October 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (11-12) , 1621-1622
Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?
- 14 October 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (11-12) , 1621-1622
Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?
- 13 August 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (5) , 648-649
Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
LINKED CONTENT: This article is linked to Kim et al paper. To view this article, visit https://doi.org/10.1111/apt.18011
- 13 August 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (5) , 648-649
Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
LINKED CONTENT: This article is linked to Kim et al paper. To view this article, visit https://doi.org/10.1111/apt.18011
- 12 June 2023
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 22 (6) , 225-228
Nephrology for the transplant hepatologist
Export
- 12 June 2023
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 22 (6) , 225-228
Nephrology for the transplant hepatologist
Export
- Open Access
- 1 November 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (21)
Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease
BACKGROUND. A pilot, single-center study showed that first-degree relatives of probands with nonalcoholic fatty liver disease (NAFLD) cirrhosis have a high risk of advanced fibrosis. We aimed to validate these findings using 2 independent cohorts from the US and Europe. METHODS. This prospective study included probands with NAFLD with advanced fibrosis, NAFLD without advanced fibrosis, and non-NAFLD, with at least 1 first-degree relative. A total of 396 first-degree relatives — 220 in a derivation cohort and 176 in a validation cohort — were enrolled in the study, and liver fibrosis was evaluated using magnetic resonance elastography and other noninvasive imaging modalities. The primary outcome was prevalence of advanced fibrosis in first-degree relatives. RESULTS. Prevalence of advanced fibrosis in first-degree relatives of probands with NAFLD with advanced fibrosis, NAFLD without advanced fibrosis, and non-NAFLD was 15.6%, 5.9%, and 1.3%, respectively (P = 0.002), in the derivation cohort, and 14.0%, 2.6%, and 1.3%, respectively (P = 0.004), in the validation cohort. In multivariable-adjusted logistic regression models, age of ≥50 years (adjusted OR [aOR]: 2.63, 95% CI 1.0–6.7), male sex (aOR: 3.79, 95% CI 1.6–9.2), diabetes mellitus (aOR: 3.37, 95% CI 1.3–9), and a first-degree relative with NAFLD with advanced fibrosis (aOR: 11.8, 95% CI 2.5–57) were significant predictors of presence of advanced fibrosis (all P < 0.05). CONCLUSION. First-degree relatives of probands with NAFLD with advanced fibrosis have significantly increased risk of advanced fibrosis. Routine screening should be done in the first-degree relatives of patients with advanced fibrosis. FUNDING. Supported by NCATS (5UL1TR001442), NIDDK (U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, P30DK120515, K23DK119460), NHLBI (P01HL147835), and NIAAA (U01AA029019); Academy of Finland grant 309263; the Novo Nordisk, EVO, and Sigrid Jusélius Foundations; and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 777377. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the EFPIA.
- 1 November 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (21)
Open AccessRisk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease
BACKGROUND. A pilot, single-center study showed that first-degree relatives of probands with nonalcoholic fatty liver disease (NAFLD) cirrhosis have a high risk of advanced fibrosis. We aimed to validate these findings using 2 independent cohorts from the US and Europe. METHODS. This prospective study included probands with NAFLD with advanced fibrosis, NAFLD without advanced fibrosis, and non-NAFLD, with at least 1 first-degree relative. A total of 396 first-degree relatives — 220 in a derivation cohort and 176 in a validation cohort — were enrolled in the study, and liver fibrosis was evaluated using magnetic resonance elastography and other noninvasive imaging modalities. The primary outcome was prevalence of advanced fibrosis in first-degree relatives. RESULTS. Prevalence of advanced fibrosis in first-degree relatives of probands with NAFLD with advanced fibrosis, NAFLD without advanced fibrosis, and non-NAFLD was 15.6%, 5.9%, and 1.3%, respectively (P = 0.002), in the derivation cohort, and 14.0%, 2.6%, and 1.3%, respectively (P = 0.004), in the validation cohort. In multivariable-adjusted logistic regression models, age of ≥50 years (adjusted OR [aOR]: 2.63, 95% CI 1.0–6.7), male sex (aOR: 3.79, 95% CI 1.6–9.2), diabetes mellitus (aOR: 3.37, 95% CI 1.3–9), and a first-degree relative with NAFLD with advanced fibrosis (aOR: 11.8, 95% CI 2.5–57) were significant predictors of presence of advanced fibrosis (all P < 0.05). CONCLUSION. First-degree relatives of probands with NAFLD with advanced fibrosis have significantly increased risk of advanced fibrosis. Routine screening should be done in the first-degree relatives of patients with advanced fibrosis. FUNDING. Supported by NCATS (5UL1TR001442), NIDDK (U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, P30DK120515, K23DK119460), NHLBI (P01HL147835), and NIAAA (U01AA029019); Academy of Finland grant 309263; the Novo Nordisk, EVO, and Sigrid Jusélius Foundations; and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 777377. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the EFPIA.
- 25 August 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (7) , 880-889
Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
Summary: Background: Nonalcoholic steatohepatitis (NASH) is a common cause of chronic liver disease. There is a major need to understand the efficacy of different pharmacological agents for the treatment of NASH.Aim: To assess the relative rank‐order of different pharmacological interventions in fibrosis improvement and NASH resolution.Methods: A comprehensive search of several databases was conducted by an experienced librarian. We included randomised controlled‐trials (RCTs) comparing pharmacological interventions in patients with biopsy‐proven NASH. The primary outcome was ≥1 stage improvement in fibrosis. The secondary outcome was NASH resolution.Results: A total of 26 RCTs with 23 interventions met the eligibility criteria. Lanifibranor and obeticholic acid had the highest probability of being ranked the most effective intervention for achieving ≥1 stage of fibrosis improvement (SUCRA 0.78) and (SUCRA 0.77), respectively. For NASH resolution, semaglutide, liraglutide and vitamin E plus pioglitazone had the highest probability of being ranked the most effective intervention for achieving NASH resolution (SUCRA 0.89), (SUCRA 0.84) and (SUCRA 0.83), respectively. Lanifibranor, obeticholic acid, pioglitazone and vitamin E were significantly better than placebo in achieving ≥1 stage of fibrosis improvement. Conversely, semaglutide, liraglutide, vitamine E plus pioglitazone, pioglitazone, lanifibranor and obeticholic acid were significantly better than placebo in achieving NASH resolution.Conclusion: These data provide relative rank‐order efficacy of various NASH therapies in terms of their improvements in liver fibrosis and NASH resolution. Therapies that have been shown to improve NASH resolution may be combined with therapies that have an antifibrotic effect to further boost treatment response rate in future.
- 25 August 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (7) , 880-889
Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
Summary: Background: Nonalcoholic steatohepatitis (NASH) is a common cause of chronic liver disease. There is a major need to understand the efficacy of different pharmacological agents for the treatment of NASH.Aim: To assess the relative rank‐order of different pharmacological interventions in fibrosis improvement and NASH resolution.Methods: A comprehensive search of several databases was conducted by an experienced librarian. We included randomised controlled‐trials (RCTs) comparing pharmacological interventions in patients with biopsy‐proven NASH. The primary outcome was ≥1 stage improvement in fibrosis. The secondary outcome was NASH resolution.Results: A total of 26 RCTs with 23 interventions met the eligibility criteria. Lanifibranor and obeticholic acid had the highest probability of being ranked the most effective intervention for achieving ≥1 stage of fibrosis improvement (SUCRA 0.78) and (SUCRA 0.77), respectively. For NASH resolution, semaglutide, liraglutide and vitamin E plus pioglitazone had the highest probability of being ranked the most effective intervention for achieving NASH resolution (SUCRA 0.89), (SUCRA 0.84) and (SUCRA 0.83), respectively. Lanifibranor, obeticholic acid, pioglitazone and vitamin E were significantly better than placebo in achieving ≥1 stage of fibrosis improvement. Conversely, semaglutide, liraglutide, vitamine E plus pioglitazone, pioglitazone, lanifibranor and obeticholic acid were significantly better than placebo in achieving NASH resolution.Conclusion: These data provide relative rank‐order efficacy of various NASH therapies in terms of their improvements in liver fibrosis and NASH resolution. Therapies that have been shown to improve NASH resolution may be combined with therapies that have an antifibrotic effect to further boost treatment response rate in future.
- Open Access
- 31 July 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (4) , 511-512
Editorial: trends in alcohol use and alcohol‐related liver disease in the US population
- 31 July 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (4) , 511-512
Open AccessEditorial: trends in alcohol use and alcohol‐related liver disease in the US population
- 7 October 2019
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 03 (04) , 305-313
Medical Management after Liver Transplantation
Medical management of the liver transplant recipient requires consideration of the complex interactions between the transplanted liver, immunosuppression and all organ systems. An aging transplant population, improvement in long-term liver transplant outcomes, and the increase in nonalcoholic fatty liver disease as an indication for transplant have amplified the number of co-morbidities among post-transplant patients. In addition to balancing immunosuppression with infection risk, medical management of the transplanted patient includes monitoring for, and treating, recurrence of the primary liver disease, metabolic syndrome, cardiovascular disease, and post-transplant neurologic and renal dysfunction. Additionally, general healthcare maintenance such as management of osteoporosis, immunizations, and screening for malignancy are essential in this high-risk population. In this review, we summarize the evidence behind best practices for the current medical management of the post liver transplant patient.
- 7 October 2019
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 03 (04) , 305-313
Medical Management after Liver Transplantation
Medical management of the liver transplant recipient requires consideration of the complex interactions between the transplanted liver, immunosuppression and all organ systems. An aging transplant population, improvement in long-term liver transplant outcomes, and the increase in nonalcoholic fatty liver disease as an indication for transplant have amplified the number of co-morbidities among post-transplant patients. In addition to balancing immunosuppression with infection risk, medical management of the transplanted patient includes monitoring for, and treating, recurrence of the primary liver disease, metabolic syndrome, cardiovascular disease, and post-transplant neurologic and renal dysfunction. Additionally, general healthcare maintenance such as management of osteoporosis, immunizations, and screening for malignancy are essential in this high-risk population. In this review, we summarize the evidence behind best practices for the current medical management of the post liver transplant patient.